Notably, the ICE3 trial recently published their 5-year follow-up of 194 women aged 60 years or older with low grade, 1.5 cm or smaller, HR+ and HER2− invasive ductal carcinoma who underwent cryoablation, where they noted a 4.3% recurrence rate and 96.7% breast cancer survival rate.20 Active surveillance of DCIS is currently being studied in comparison with guideline-concordant care (surgery with or without radiation) in the COMET trial. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.